Overview

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:
0

Participant gender:
All

Summary

This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.

Phase:

Phase 1/Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Rockefeller University

Collaborator:

Facet Biotech

Treatments:

Daclizumab
Immunoglobulin G

Criteria

Inclusion Criteria

1. Male or female patients with chronic psoriasis vulgaris (disease stable or worsening
for > 6 months). Patients age 16 - 21 will be considered on a case to case basis.

For those patients under the age of 18, parental consent will be obtained.

2. Extensive skin involvement.

3. Scale, thickness, and erythema in individual psoriasis lesions of at least moderate
intensity.

4. Psoriasis treated with emollients only for 2 weeks prior to treatment

5. Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris
involving more than 5% of the body surface.

6. Patients that are appropriate for treatment with UVB.

Exclusion Criteria:

1. Positive serology for HIV, Hepatitis B, or Hepatitis C.

2. Positive β-HCG titer. For women of childbearing potential, unwillingness or inability
to use a contraceptive device during this study if negative for β-HCG.

3. Guttate psoriasis, pustular psoriasis, or whole body erythroderma.

4. Active infection or persistent fever of unknown origin.

5. Major concurrent illness, which could worsen following treatment with anti-TAC.